Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.42 |
| ▸ | CA2 | P00918 | 6/20 | 0.42 |
| ▸ | CA4 | P22748 | 6/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 4/20 | 0.31 |
| ▸ | RHEB | Q15382 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10433422 | 0.96 | CA1 (0.38) | CA1CA2CA4FKBP1A | |
| SCHEMBL24814039 | 0.96 | CA1 (0.38) | CA1CA2CA4FKBP1A | |
| SCHEMBL7296965 | 0.81 | PABPC1 (0.33) | FKBP1A | |
| SCHEMBL7291318 | 0.81 | PABPC1 (0.33) | FKBP1A | |
| SCHEMBL3779935 | 0.78 | — | — | |
| SCHEMBL17544125 | 0.78 | — | — | |
| SCHEMBL17544124 | 0.78 | — | — | |
| SCHEMBL8943504 | 0.78 | FKBP1A (0.32) | FKBP1A | |
| SCHEMBL9133269 | 0.78 | FKBP1A (0.32) | FKBP1A | |
| SCHEMBL9470607 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035379-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-02-05 | — | — | US | disclosed |
| US-12534475-B2 | Bicyclic pyridine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2026-01-27 | — | — | US | disclosed |
| US-12077546-B2 | Bicyclic pyridine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-09-03 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240228505-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240150370-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4324834-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-21 | — | — | EP | disclosed |
| CN-117177977-A | Bicyclic pyridine derivatives | 住友制药株式会社 | 2023-12-05 | — | — | CN | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2022215754-A1 | BICYCLIC PYRIDINE DERIVATIVE | 住友ファーマ株式会社 | 2022-10-13 | — | — | WO | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-7125865-B2 | Therapeutic compounds for treating dyslipidemic conditions | MERCK & CO., INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050239769-A1 | Therapeutic compounds for treating dyslipidemic conditions | MERCK SHARP & DOHME CORP. | 2005-10-27 | — | — | US | disclosed |
| EP-1534696-A1 | THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004011448-A1 | THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS | MERCK & CO., INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035379-A1 | BICYCLIC PYRIDINE DERIVATIVE | CBR1, CBR3, CYP2B6 | CA1 882/4885CA2 620/4885CA4 785/4885 |
| US-20240228505-A1 | BICYCLIC PYRIDINE DERIVATIVE | CBR1, CBR3, CYB5R3 | CA1 1360/4885CA2 852/4885CA4 1867/4885 |
| US-12077546-B2 | Bicyclic pyridine derivative | CBR1, CBR3, CYB5R3 | CA1 1360/4885CA2 852/4885CA4 1867/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CA1 4622/4885CA2 4617/4885CA4 4210/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CA1 4622/4885CA2 4617/4885CA4 4210/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CA1 4622/4885CA2 4617/4885CA4 4210/4885 |
| US-20240150370-A1 | BICYCLIC PYRIDINE DERIVATIVE | CBR1, CBR3, CYB5R3 | CA1 1360/4885CA2 852/4885CA4 1867/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CA1 4622/4885CA2 4617/4885CA4 4210/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CA1 4622/4885CA2 4617/4885CA4 4210/4885 |
| US-20050239769-A1 | Therapeutic compounds for treating dyslipidemic conditions | NR1H2, NR1H3, LDLR | CA1 4411/4885CA2 4722/4885CA4 4738/4885 |
| US-12534475-B2 | Bicyclic pyridine derivative | CBR1, CYP2B6, CBR3 | CA1 1137/4885CA2 981/4885CA4 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.